Sycamore Partners is in advanced talks to sell Boots, the 176-year-old UK pharmacy chain, to the Canadian branch of the Weston family for $9bn (£7bn). A deal could close as soon as next week. If completed, it would mark the Westons' return to the UK high street after selling Selfridges for £4bn in 2022. The mechanics here are textbook private equity decomposition. Sycamore acquired the entire Walgreens Boots Alliance for $23.7bn in 2025, immediately split it into five standalone companies, and is now selling off the pieces individually. Boots is the first major carve-out to near completion, following a failed attempt to sell to Australia's Sigma Healthcare at a $10bn valuation this summer. The Weston family operates through two distinct branches. The Canadian side — the prospective buyers — controls grocery giant Loblaws and Shoppers Drug Mart, Canada's dominant pharmacy chain. The UK branch, operating separately through Associated British Foods, holds a majority stake in Primark. The acquisition would slot Boots alongside Shoppers Drug Mart in a pharmacy portfolio with clear operational synergies. Boots itself is performing well by high street standards: revenues rose 3.2% to £7.5bn in the year to August 2025, with pre-tax profit climbing 25% to £337m. Weight loss drugs and beauty products drove the gains. The business operates 1,800 stores and employs approximately 51,000 people, with about 6,000 at its Beeston headquarters near Nottingham. The ownership carousel is the real story. Since 2006, Boots has passed through Alliance Unichem, KKR, Walgreens (first a 45% stake in 2012, full takeover in 2014), and now Sycamore — each transaction generating fees, leverage, and ownership changes while the same pharmacists fill the same prescriptions. The $9bn price tag is roughly 2.6x revenue and 21x pre-tax profit, rich enough to deliver Sycamore a handsome return on its allocated portion of the $23.7bn Walgreens deal. The Westons bring operational knowledge in pharmacy retail that Sycamore, as a financial buyer, never intended to deploy. Whether they invest in Boots' infrastructure or treat it as a cash-generating asset to lever is the question that matters for 51,000 employees and millions of customers. The track record with Shoppers Drug Mart suggests the former, but the price demands returns that constrain generosity. Founded in Nottingham in 1849 by John Boot, the chain has survived every ownership transition so far. The question is not whether Boots endures — it will — but how much value gets extracted in each pass through the financial system versus reinvested in the stores, staff, and communities that generate the cash in the first place.
